Showing results (431-440 of 494) with videos related to
Sort By:
Pageof 50
Nature|October 15, 2020
Inherited myeloproliferative neoplasm risk affects haematopoietic stem cellsErik L Bao, Satish K Nandakumar, Xiaotian Liao, et al.The Journal of Experimental Medicine|April 13, 2019
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF mutationSusana García-Silva, Alberto Benito-Martín, Sara Sánchez-Redondo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.European Journal of Cancer (Oxford, England : 1990)|January 24, 2024
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international studyMario Mandalà, Paul Lorigan, Maria Chiara Sergi, et al.Annals of Surgery|December 22, 2025
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar)Alessandra Borghi, Marco Fiore, Gabriele Tiné, et al.Eclinicalmedicine|March 5, 2026
Neoadjuvant radiotherapy for primary retroperitoneal well-differentiated liposarcoma: a Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) propensity score matched analysisMark Fairweather, Megan Sulciner, Joshua S Jolissaint, et al.The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.Nature Medicine|January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trialMichael C Heinrich, Robin L Jones, Suzanne George, et al.European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapyAmelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.European Journal of Cancer (Oxford, England : 1990)|September 5, 2024
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)Mario Mandalà, Andrea Ferrari, Ines B Brecht, et al.Pageof 50